UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

TEVA PHARMACEUTICALS USA, INC. *Petitioner*

v.

CORCEPT THERAPEUTICS, INC. Patent Owner

> Case No: <u>Unassigned</u> U.S. Patent No. 10,195,214

Title: CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATORS AND CYP3A INHIBITORS

DECLARATION OF ATUL KAUSHIK

DOCKET

Δ

I, Atul Kaushik, hereby declare as follows:

1. I am over the age of eighteen (18) and competent to make this declaration.

2. I understand that this Declaration accompanies a petition for PGR involving U.S. Patent No. 10,195,214 ("the '214 patent") (TEVA1001).

3. I have personal knowledge of all the facts contained in this declaration.

4. I am Senior Director at Teva Pharmaceuticals USA, Inc. My business address is Plot No. K-7, MIDC, Additional Ambernath (E), Dist.-Thane, India-421506. In this role, I am leading Formulation Research and Development Department. As part of my duties, I routinely review FDA approval packages for branded drugs for which Teva seeks FDA approval to manufacture and distribute a generic equivalent. I, or one of my colleagues at Teva, access these materials by downloading them from the FDA's website.

5. On December 15, 2017, Teva filed Abbreviated New Drug Application No. 211436 seeking to market a generic version of Korlym[®] (mifepristone) Tablets, 300 mg. Korlym is the subject of Corcept Therapeutic, Inc.'s New Drug Application No. 202107, which was approved by the FDA on February 17, 2012.

- 1 -

6. In April 2016, in connection with Teva's preparation of ANDA No.
211436, my colleague Pritesh Jain downloaded all the materials in the Drug
Approval Package for Korlym from the FDA's website. *See*

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107_korlym_toc.cf m. This webpage's "Date created" is listed as July 6, 2012. I know that Mr. Jain downloaded the material in early 2016 because it was part of our preparation of ANDA No. 211436. The documents from the Korlym Drug Approval Package were electronically saved on Teva's internal network in April 2016, as shown in the screenshot below, which I took on April 26, 2019.

Status_files Torig1s000Admincorres.pdf Torig1s000ChemR.pdf Torig1s000CrossR.pdf Torig1s000CrossR.pdf Torig1s000MeR.pdf Torig1s000NameR.pdf Torig1s0000Et.ist.pdf Torig1s000DEt.ist.pdf	12/12/2017 3;50 PM 29/94/2015 10:08 29/04/2015 5:24 PM 03/05/2016 5:54 PM 28/04/2016 4:50 PM 28/04/2016 4:59 PM 29/04/2016 5:56 PM	File folder Adobe Acrobat D Adobe Acrobat D Adobe Acrobat D Adobe Acrobat D Adobe Acrobat D	4,361 KB 3,743 KB 7,372 KB 887 KB	PILpdf Propertie			
70rig1s000Admincorres.pdf 70rig1s000ChemR.pdf 70rig1s000CnossR.pdf 70rig1s000CrossR.pdf 70rig1s000MedR.pdf 70rig1s000MedR.pdf 70rig1s000MedR.pdf	29/04/2015 10:08 29/04/2016 5:24 PM 03/05/2016 5:54 PM 28/04/2016 4:50 PM 28/04/2015 4:59 PM 20/04/2016 5:26 PM	Adobe Acrobat D Adobe Acrobat D Adobe Acrobat D Adobe Acrobat D Adobe Acrobat D	3,743 KB 7,372 KB 887 KB	General Security	Details Previous Versions		
70rig1:000ChemR.pdf 7orig1:000Cnipharmr.pdf 70rig1:0000CrossR.pdf 70rig1:000MedR.pdf 70rig1:000MemR.pdf 70rig1:0000EList.pdf	28/04/2016 5:24 PM 03/05/2016 5:54 PM 28/04/2016 4:50 PM 28/04/2015 4:59 PM 28/04/2015 5:26 PM	Adobe Acrobat D Adobe Acrobat D Adobe Acrobat D Adobe Acrobat D	3,743 KB 7,372 KB 887 KB				
7Orig1s000CrossR.pdf 7Orig1s000MedR.pdf 7Orig1s000NameR.pdf 7Orig1s000OEList.pdf	28/04/2016 4:50 PM 28/04/2015 4:59 PM 28/04/2016 5:26 PM	Adobe Acrobat D Adobe Acrobat D	887 KB	Property	Value		
7Orig1s000CrossR.pdf 7Orig1s000MedR.pdf 7Orig1s000NameR.pdf 7Orig1s000OEList.pdf	28/04/2015 4:59 PM 29/04/2016 5:26 PM	Adobe Acrobat D	887 KB	Property	Value		
70rig1s000MedR.pdf 70rig1s000NameR.pdf 70rig1s0000EList.pdf	28/04/2016 5:26 PM	Adobe Acrobat D			And the second	•	
70rig1s000NameR.pdf 70rig1s0000EList.pdf			2.214 KB	File			
7Orig1s000OEList.pdf	20/04/2016 1.42 014	Adobe Acrobat D	712 KB	Name	PIL.pdf		
	23/84/2016 4:43 PM	Adobe Acrobat D	95 KB	Type Folder path	Adobe Acrobal Document \\10.202.98.21\public\PUBLIC\FRD\		
	29/04/2016 10:09	Adobe Acrobat D	5.617 KB	Size	240 KB		
7Orig1s000PharmR.pdf	20/04/2016 5:43 PM	Adobe Acrobat D	5.503 KB	Date created	28/04/2016 4:50 PM		
7Orig1s000RiskR.pdf	29/04/2016 9:46 AM	Adobe Acrobat D	121 KB	Date modified	28/04/2016 4:50 PM		
7Orig1s000StatR.pdf	29/04/2015 10:01	Adobe Acrobat D	2.455 KB	Allabutes	A		
70rig1s000SumR.pdf	28/04/2016 4:42 PM	Adobe Acrobat D	1.209 KB				
7s000lbl.pdf	28/04/2016 3:21 PM	Adobe Acrobat D	349 KB				
7s000ltr.pdf	28/84/2016 3:35 PM	Adobe Acrobat D	90 KB				
med Label.pdf	29/04/2016 10:19	Adobe Acrobat D	381 KB	Composed	10.00.00.01		
ŀ	28/84/2015 4:50 PM	Adobe Acrobat D	241 KB				
Status.htm	04/05/2016 3:23 PM	HTML Document	35 KB				
				Remove Propertie	and Personal Information		
					OK Cencel Apply		
7 7 7 7	Orig1s000StatR.pdf Orig1s000SumR.pdf s000lbl.pdf s000ltr.pdf label.pdf	Orig1:0005txtR.pdf 29/04/2015 10:01 Orig1:0005umR.pdf 20/04/2015 4:42 PM :0001b1.pdf 20/04/2015 3:35 PM :0000tr.pdf 28/04/2015 3:35 PM :ed1abel.pdf 29/04/2015 10:01 :28/04/2015 10:01 28/04/2015 4:50 PM	Orig1:000StatR.pdf 23/04/2015 10:01 Adobe Acrobat D Orig1:000SumR.pdf 28/04/2015 4:42 PM Adobe Acrobat D 00001b.pdf 28/04/2015 3:21 PM Adobe Acrobat D 00000tr.pdf 28/04/2015 3:21 PM Adobe Acrobat D 0000tr.pdf 28/04/2015 3:21 PM Adobe Acrobat D 0000tr.pdf 28/04/2015 3:21 PM Adobe Acrobat D 0000tr.pdf 28/04/2015 3:21 PM Adobe Acrobat D 02/04/2015 1:01:01 Adobe Acrobat D Adobe Acrobat D 041 bael.pdf 28/04/2015 1:01:01 Adobe Acrobat D 28/04/2015 4:50 PM Adobe Acrobat D Adobe Acrobat D	Orig1:000StatR.pdf 29/04/2015 10:01 Adobe Acrobat D 2,455 kB Orig1:000SumR.pdf 28/04/2015 4:42 PM Adobe Acrobat D 1,203 YB 0000bl.pdf 28/04/2015 3:21 PM Adobe Acrobat D 348 KB 0000bl.pdf 28/04/2015 3:35 PM Adobe Acrobat D 94 KB 9000br.pdf 28/04/2015 3:35 PM Adobe Acrobat D 90 KB 28/04/2015 3:35 PM Adobe Acrobat D 90 KB 28/04/2015 3:35 PM Adobe Acrobat D 90 KB 28/04/2015 4:50 PM Adobe Acrobat D 201 KB	Orig1:000Scatt.pdf 23/04/2015 10:01 Adobe Acrobat D 2,455 %B Utbe/web Orig1:000ScmR.pdf 20/04/2015 442 PM Adobe Acrobat D 1,209 YB Office availability 0000bl.pdf 20/04/2015 442 PM Adobe Acrobat D 1,209 YB Office availability 0000bl.pdf 20/04/2015 312 PM Adobe Acrobat D 349 KB Dwine 0000bl.pdf 20/04/2015 3135 PM Adobe Acrobat D 341 YB Dwine 28/04/2015 4350 PM Adobe Acrobat D 241 KB Computer Computer 28/04/2015 313 23 PM HTML Document 35 KB United availability Computer	Orig1:0005xxtR.pdf 23/04/2015 18:01 Adobe Acrobat D 2,455 KB Orig1:0005xmR.pdf 22/04/2015 Ad2 PM Od00blopdf 22/04/2015 222 PM 3000blopdf 22/04/2015 322 PM 22/04/2015 322 PM Adobe Acrobat D 30 KB 3000br.pdf 22/04/2015 322 PM 22/04/2015 323 PM Adobe Acrobat D 301 KB 22/04/2015 323 PM Adobe Acrobat D 301 KB 22/04/2015 323 PM HTML Document 35 KB	Orig1:0005cmR.pdf 23/04/2015 18:01 Adobe Acrobat D 2,455 KB Orig1:0005cmR.pdf 23/04/2015 Ad2 PM Adobe Acrobat D 1,209 HB 00001b;pdf 23/04/2015 3122 PM Adobe Acrobat D 345 KB 00001b;pdf 23/04/2015 3123 PM Adobe Acrobat D 90 KB 020147:pdf 23/04/2015 3135 PM Adobe Acrobat D 90 KB 23/04/2015 3123 PM Adobe Acrobat D 311 RB 23/04/2015 3123 PM HTML Document 351 KB

- 2 -

DOCKF

Find authenticated court documents without watermarks at docketalarm.com.

7. The file named "202107s000lbl.pdf" is a copy of the original FDAapproved label for Korlym that was downloaded from the FDA website. I confirm that Mr. Jain downloaded "202107s000lbl.pdf" in April 2016 as a part of the preparation for Teva's filing ANDA No. 211436. This document is attached to Teva's petition as Exhibit TEVA1004.

8. The file named "202107orig1s000clinpharmr.pdf" is copy of the Clinical Pharmacology Review for Korlym, Office of Clinical Pharmacology Review NDA 20687 (Addendum, KorlymTM, Mifepristone) (2012) that was downloaded from the FDA website. I confirm that Mr. Jain downloaded "202107orig1s000clinpharmr.pdf" in April 2016 as a part of the preparation for Teva's filing ANDA No. 211436. This document is attached to Teva's petition as Exhibit TEVA1005.

9. The file named "202107s000ltr.pdf" is a copy of FDA's approval letter for Korlym that was downloaded from the FDA website. I confirm that Mr. Jain downloaded "202107s000ltr.pdf" in April 2016 as a part of the preparation for Teva's filing ANDA No. 211436. This document is attached to Teva's petition as Exhibit TEVA1006.

10. I accordingly have personal knowledge that the documents attached to Teva's petition as Exhibits TEVA1004, TEVA1005, and TEVA1006 were publicly available on the FDA's website no later than April 2016.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code.

Respectfully submitted,

نعن فنيته

Atul Kaushik [Senior Director-FRD]

Date: May 7, 2019